| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2025 | Dec, 2025 | Dec, 2025 | Dec, 2025 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Ophthalix Inc (OPLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
OphthaliX Inc was incorporated in the State of Nevada on December 10, 1999. The Company is a clinical-stage biopharmaceutical company. It is engaged in developing therapeutic products for the treatment of ophthalmic disorders. It has in-licensed certain patents and patent applications protecting the use in the ophthalmic field of its current pipeline drug under development, a synthetic A3 adenosine receptor ('A3AR') agonist, CF101. CF101 is being developed by the Company to treat three ophthalmic indications: keratoconjunctivitis sicca, also known as dry eye syndrome, or DES; glaucoma, and uveitis. The Company is subject to various environmental, health and safety laws and regulations, including those governing air emissions, water and wastewater discharges, noise emissions, the use, management and disposal of hazardous, radioactive and biological materials and wastes and the cleanup of contaminated sites. It is also subject to various federal, state and international laws pertaining to health care 'fraud and abuse,' including anti-kickback laws and false claims laws.